

PARKINSON'S THERAPIES IN DEVELOPMENT

2 July 2018

Kevin McFarthing

RESEARCH/PRE-CLINICAL		CLINICAL	
Discovery	46	Phase 1	29
Pre-clinical	67	Phase 2	48
Research program	13	Phase 3	12
		Proof of concept	7
		Submitted or pre-submission	3
TOTAL	126	TOTAL	99
Symptom relief	24	Symptom relief	57
Disease modifying	101	Disease modifying	42
Not clear	1		
		TOTAL	99
TOTAL	126		
NCE	104	NCE	48
Reformulation	3	Reformulation	19
Repurpose	9	Repurpose	22
Cells	5	Cells	5
Gene therapy	1	Non-invasive surgery	1
Protein extract	1	Gene therapy	3
Target discovery	1	Botanical	1
Botanical	1		
Not clear	1		
TOTAL	126	TOTAL	99

NCE = new chemical entity

PARKINSON'S THERAPIES IN DEVELOPMENT - CLINICAL PHASE

2 July 2018

Kevin McFarthing

COMPANY	THERAPY	WHAT IS IT?	STATUS	OBJECTIVE	TYPE	LINK
Abbvie	ABBV-951	Sub-cutaneous L-DOPA/Carbidopa	Phase 1	Symptom relief	Reformulation	https://www.abbvie.com/our-science/pipeline/abbv-951.html https://clinicaltrials.gov/ct2/show/NCT03033498?term=INFLECT+EXACT+%28+%22Recruiting%22+OR+%22Not+yet+recruiting%22+OR+%22Available%22+OR+%22Active%2C+not+recruiting%22+OR+%22Enrolling+by+invitation%22+%29+%5B%5D&type=Intr&cond=parkinson%27s+disease&draw=2&rank=146
Acorda Therapeutics	CVT-301 (Inbrija)	Inhaled L-DOPA	Submitted	Symptom relief	Reformulation	http://ir.acorda.com/investors/investor-news/investor-news-details/2018/Acorda-Announces-FDA-Acceptance-of-New-Drug-Application-for-INBRIJA-levodopa-inhalation-powder/default.aspx
Acorda Therapeutics	SYN-120	Dual antagonist of 5-HT6 and 5-HT2A	Phase 2	Symptom relief (cognitive)	NCE	http://www.acorda.com/products/research-development/syn120
Addex Therapeutics	Dipraglurant	mGluR5 inhibitor	Phase 2a	Symptom relief (LID)	NCE	https://www.addextherapeutics.com/en/pipeline/clinical-pipeline/
Affiris	PD01/PD03	aSN vaccine	Phase 1	Disease modifier	NCE	https://parkinsonsnewstoday.com/2018/05/18/potential-parkinsons-vaccine-affitope-pd01a-shows-promising-long-term-results-in-phase-1-study-series/?utm_source=PAR+E-mail+List&utm_campaign=0831ff431a-RSS_WEEKLY_EMAIL_CAMPAIGN_DAILY_US&utm_medium=email&utm_term=0_62dd4fb5e3-0831ff431a-72080517
Amarantus Bioscience	Eltoprazine	5-HT partial agonist	Phase 2	Symptom relief (UD)	NCE	http://www.amarantus.com/therapeutics-pipeline/therapeutics/eltoprazine
Anmeal (was Impax Pharma)	IPX203	L-DOPA/carbidopa extended release	Phase 3	Symptom relief	Reformulation	https://investors.impaxlabs.com/news/press-releases/press-release-details/2018/Anmeal-Initiates-Phase-3-Study-for-IPX203-an-Investigational-Extended-Release-Formulation-of-Carbidopa-Levodopa-CD-LD-in-Advanced-Parkinsons-Disease-Patients/default.aspx
Anavex Life Sciences	2-73	Targets sigma receptors	Phase 1	Disease modifier	NCE	http://www.anavex.com/pipeline/
ApoPharma/Fair Park II/Cure Parkinson's Trust	Deferiprone	Iron chelator	Phase 3	Disease modifier	Repurpose	https://www.cureparkinsons.org.uk/deferiprone http://www.fairpark2.eu/index.php
Astra Zeneca (owns Bydureon)/UCL/CPT Astra Zeneca / Takeda	Exenatide (Bydureon) MEDI1341	Type 2 diabetes drug aSN antibody	Proof of concept Phase 1	Disease modifier Disease modifier	Repurpose NCE	http://www.ncbi.nlm.nih.gov/pubmed/24662192 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-takeda-establish-collaboration-to-develop-and-commercialise-medi1341-for-parkinsons-disease-25082017.html https://clinicaltrials.gov/ct2/show/NCT03272165?term=MEDI1341&rank=1
Avanir Pharmaceuticals	Nuedexta	Dextromethorphan/quinidine	Phase 1	Symptom relief (UD)	Repurpose	http://www.avanir.com/treatments/nuedexta https://www.ncbi.nlm.nih.gov/pubmed/28370447 http://onlinelibrary.wiley.com/doi/10.1002/mds.26976/full
Axovant	Nelotanserin	5HT2A inverse agonist	Phase 2	Symptom relief DLB and PDD	NCE	http://investors.axovant.com/news-releases/news-release-details/correction-axovant-announces-negative-results-in-epididine-phase
Axovant	AXO-Lenti-PD	Gene therapy	Phase 1/2	Disease modifier	Gene therapy	https://globenewswire.com/news-release/2018/06/06/1517417/0/en/Axovant-Licenses-Investigational-Gene-Therapy-for-Parkinson-s-Disease-from-Oxford-BioMedica-and-Announces-Key-Leadership-Team-Addition.html
BenevolentAI Bio	BEN-2001	Bavisant	Phase 2b	Symptom relief (daytime sleepiness)	Repurpose	https://clinicaltrials.gov/ct2/show/NCT03194217?term=INFLECT+EXACT+%28+%22Recruiting%22+OR+%22Not+yet+recruiting%22+OR+%22Available%22+OR+%22Active%2C+not+recruiting%22+OR+%22Enrolling+by+invitation%22+%29+%5B%5D&type=Intr&cond=parkinson%27s+disease&draw=4
BioElectron (formerly Edison Pharna)	BioE-589	Improves mitochondrial function	Phase 2a	Disease modifier	NCE	http://www.bioelectron.com
Biogen	BIB054	aSN antibody	Phase 2	Disease modifier	NCE	https://www.biogen.com/en_us/pipeline.html
Bristol University	Rivastigmine	Cholinesterase inhibitor	Phase 3	Symptom relief (balance)	Repurpose	https://www.parkinsons.org.uk/news/uk-wide-trial-test-treatment-balance-walking-and-falls
Cavion	CX-8998	Cav3 modulator	Phase 2	Symptom relief	NCE	http://cavionpharma.com/technology
Celavie Biosciences	OK99	Stem cells	Phase 1	Disease modifier	Stem cells	http://www.celavie.com/celavie/product-development/
Clera	CLR4001	Dopamine receptor modulator	Phase 2a	Symptom relief	NCE	http://www.clera.com/parkinsons/
Cleaveland/Domain	CVXL-107	Glutamate release inhibitor	Phase 2a	Symptom relief	NCE	http://www.cleavelandpharma.com/en/cvxl-0107/
Colorado University, Denver	Phenylbutyrate	Thought to clear aSN	Phase 1	Disease modifier	Repurpose	https://clinicaltrials.gov/ct2/show/NCT02046434
Contera Pharma	JM-010	5-HT1 receptor agonist combinations	Phase 2a	Symptom relief (LID)	NCE	http://www.conterapharma.com/page/rnd.html https://www.google.com/patents/EP2627328A1
Cure Parkinson's Trust/UCL	Ambroxol	Gcase enhancer	Proof of concept	Disease modifier	Repurpose	https://clinicaltrials.gov/ct2/show/NCT02941822
Cure Parkinson's Trust	Simvastatin	Cholesterol lowering statin	Proof of concept	Disease modifier	Repurpose	https://www.cureparkinsons.org.uk/News/simvastatin-trial-underway
Dart Neuroscience	HT-3951	MAO-B inhibitor	Phase 2	Symptom relief	NCE	http://dartneuroscience.com/Company.php

COMPANY	THERAPY	WHAT IS IT?	STATUS	OBJECTIVE	TYPE	LINK
Denali Therapeutics	DNL-201	Lysosomal function enhancer	Phase 1	Disease modifier	NCE	https://www.denalitherapeutics.com/develop/#pipeline
Denali Therapeutics	DNL-151	Lysosomal function enhancer	Phase 1	Disease modifier	NCE	https://www.denalitherapeutics.com/develop/#pipeline
Dizlin	Infudopa	Sub-cutaneous L-DOPA	Phase 2?	Symptom relief	Reformulation	http://dizlin.se/about-dizlin/
Dong-A	DA-9805	Botanical extract	Phase 2a	Disease modifier	Botanical	https://clinicaltrials.gov/ct2/show/NCT03189563
Eli Lilly	LY3154207	D1 agonist	Phase 2	Symptom relief (PD dementia)	NCE	https://parkinsonsnewstoday.com/2018/05/15/eli-lilly-recruiting-trial-test-ly3154207-parkinsons-dementia/?utm_source=PAR+E-mail+List&utm_campaign=85b2200391-RSS_WEEKLY_EMAIL_CAMPAIGN_DAILY_US&utm_medium=email&utm_term=0_62dd4fb5e3-85b2200391-72080517
Enterin	ENT-01 (Kenterin)	Displaces aSN aggregates	Phase 2a	Disease modifier	NCE	http://enterininc.com/clinical-study/ http://enterininc.com/kenterin/
Genervon	GM608	Motoneuronotrophic factor (MNTF)	Phase 2a	Disease modifier	NCE	https://www.genervon.com/pipeline/
GNT Pharma	Ropesalazine	mPGES-1 inhibition; ROS scavenger	Phase 1	Disease modifier	NCE	http://gntpharma.com/en/pipeline/aad-2004-neurological-diseases/
Herantis	CDNF	Cerebral dopamine neurotrophic factor	Phase 1/2	Disease modifier	NCE	http://herantis.com/pipeline/pipeline-overview/
Hisamitsu	HP-3000	Ropinriole patch	Phase 3	Symptom relief	Reformulation	http://global.hisamitsu.pdf/news_release_F_180227.pdf
Hopitax de Paris	Buspirone	SHT1A agonist	Phase 3	Symptom relief (LD)	Repurpose	https://www.clinicaltrials.gov/ct2/show/NCT02617017?term=buspirone&cond=Parkinson+Disease&rank=1
Impel NeuroPharma	INP-103	Inhaled L-DOPA	Phase 2a	Symptom relief	Reformulation	http://impelp.com/treatments/parkinsons-treatment/ https://clinicaltrials.gov/ct2/show/NCT03541356?term=impel&rank=1
InSightec Ltd	ExAblate Neuro	MR guided focused ultrasound	Phase 3 ("pivotal")	Symptom relief	Non-invasive surgery	https://www.insightec.com/news-events/press-releases/2018/focused-ultrasound-extends-its-focus-insightec-initiates-parkinson-s-disease-study-with-first-patient-treated-with-incisionless-brain-surgery
Intec Pharma	Accordion Pill	L-DOPA/carbidopa extended release	Phase 3	Symptom relief	Reformulation	http://intecpharma.com/pipeline/ap-cdd/
Integrative research laboratories	IRL 790	"Psychomotor stabiliser"	Phase 2	Symptom relief (LD)	NCE	http://www.irlab.se/programmes/
Integrative research laboratories	IRL 752	"Cortical enhancer"	Phase 2	Symptom relief (PD dementia)	NCE	http://www.irlab.se/programmes/
International Stem Cell Corporation	ISC-hpNSC	Neural stem cells	Phase 1	Disease modifier	Stem cells	http://investors.internationalstemcell.com/profiles/investor/ResLibraryView.aspx?ResLibraryID=87901&BzID=1468&g=583&Nav=0&LangID=1&s=0
Intra-cellular Therapies	ITI-214	PDE-1 inhibitor	Phase 1/2	Symptom relief	NCE	http://ir.intracellulartherapies.com/releasedetail.cfm?ReleaseID=1042518&t=1&cn=ZmxleGlibGVfcmVjc18y&refsrc=email&iid=8d639e4331264005ac9cd4c8257f6528&uid=155908569&nid=244+285282312
Io Therapeutics	IRX4204	RXR agonist (nuclear retinoid receptors)	Phase 1	Disease modifier	NCE	http://io-therapeutics.com/programs/4204-2/
Jazz Pharmaceuticals	JZP-110	Selective dopamine and norepinephrine reuptake inhibitor	Phase 2	Symptom relief (daytime sleepiness)	NCE	http://investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-newsArticle&ID=2244429
Kainos Medicine	KM819	FAF-q inhibitor	Phase 1	Disease modifier	NCE	http://www.kainosmedicine.com/?c=user&cmd=eng03_08
Kissei	KDT-3594	DA receptor stimulation	Phase 1	Symptom relief	NCE	http://www.kissei.co.jp/e_contents/rd/pipeline/
Kyowa Hakko	Istradefylline (Nouriast)	A2a receptor antagonist	NDA in presubmission (marketed in Japan)	Symptom relief (LD)	NCE	http://www.kyowa-kirin.com/research_and_development/pipeline/
Kyowa Hakko	KW6356	A2a receptor antagonist	Phase 2	Symptom relief	NCE	http://www.kyowa-kirin.com/research_and_development/pipeline/
Ligand Pharmaceuticals	Aplindore	D2 agonist	Phase 2	Symptom relief	NCE	http://www.ligand.com/licensing-opportunities/aplindore
Living Cell Technologies	NTCELL	Encapsulated choroid plexus cells	Phase 2b	Disease modifier	Cells	http://www.lctglobal.com/products/ntcell/development-to-date
Lundbeck/Prexton Therapeutics/Domain Lundbeck	Foliglurax Lu AF28996.	mGlu4 inhibitor ?	Phase 2 Phase 1	Symptom relief Symptom relief	NCE NCE	http://www.lundbeck.com/global/brain-disorders/pipeline https://www.lundbeck.com/global/about-us/features/2018/lundbeck-starts-clinical-development-of-potential-new-treatment-of-parkinsons-di
Luye Pharma	LY03003	Rotigotine extended release	Phase 3	Symptom relief	Reformulation	http://www.luye.cn/lyue_en/uploads//2018-04/11_1523418115_0q983w.pdf
Medgenesis Therapeutix/ U of Bristol/PUK/CPT/MJFF	BVF-014	GDNF	Phase 2	Disease modifier	NCE	http://medgenesis.com/news.htm
Michael J Fox Foundation	Isradipine	Calcium channel blocker	Phase 3	Symptom relief	Repurpose	https://www.michaeljfox.org/foundation/news-detail.php?record-pace-of-recruitment-speeds-isradipine-trial
Michael J Fox Foundation/NIC-PD	Nicotine patch	Nicotine	Phase 2	Disease modifier	Repurpose	https://www.michaeljfox.org/files/062317_MJFF_Repurposed_Therapies_Guide.pdf
Michael J Fox Foundation / U of Rochester	Buspirone	Anxiolytic 5HT1A agonist	Phase 2	Symptom relief (anti-anxiety)	Repurpose	https://www.clinicaltrials.gov/ct2/show/NCT02803749?term=buspirone&cond=Parkinson+Disease&rank=1
Michigan University	Clarithromycin	GABA-A modulator	Proof of concept	Symptom relief	Repurpose	https://clinicaltrials.gov/ct2/show/study/NCT03440112
Minnesota University	UDCA (ursodeoxycholic acid)	Improves mitochondrial function	Phase 1	Disease modifier	Repurpose	https://clinicaltrials.gov/ct2/show/NCT02967250
Mitsubishi Tanabe/Neuroderm	ND0612	Sub-cutaneous L-DOPA	Phase 2	Symptom relief	Reformulation	https://www.mt-pharma.co.jp/e/develop/pipeline/e_pipeline1803.pdf
Mitsubishi Tanabe/Neuroderm	ND0701	Sub-cutaneous apomorphine	Phase 1	Symptom relief	Reformulation	https://www.mt-pharma.co.jp/e/develop/pipeline/e_pipeline1803.pdf
Neurmedix (ex-Harbor Therapeutics)	NE3107 (HE3286)	Anti-inflammatory	Phase 1	Symptom relief (LD)	NCE	http://www.neurmedixinc.com/development-pipeline/
Neurogeneration		Stem cells	Phase 1	Disease modifier	Stem cells	http://www.neurogeneration.com
Neurohealing Pharmaceuticals	NH004	Tropicamide thin film	Phase 2	Symptom relief (drooling)	Reformulation	http://www.neurohealing.com/products/#tab-73720359-e601-1
Neuropore + UCB	NPT 200-11/UCB-1332	Inhibitor of aSN aggregation	Phase 1	Disease modifier	NCE	http://www.neuropore.com/programs/
Novartis/MJFF/CPT/Van Andel	Nilotinib	c-Abi inhibitor	Phase 2	Disease modifier	Repurpose	https://www.clinicaltrials.gov/ct2/results?cond=Parkinson+Disease&term=nilotinib&cntry=&state=&city=&dist=
Novo Nordisk/Cure Parkinson's Trust/Cedars-Sinai	Liraglutide	GLP-1 agonist	Proof of concept	Disease modifier	Repurpose	https://www.clinicaltrials.gov/ct2/show/NCT02953665?term=liraglutide&cond=Parkinson+Disease&rank=1
Oregon Health & Science University	Buspirone/amantadine	SHT1A agonist + amantadine	Phase 2	Symptom relief (LD)	Repurpose	https://www.clinicaltrials.gov/ct2/show/NCT02589340?term=buspirone&cond=Parkinson+Disease&rank=3

COMPANY	THERAPY	WHAT IS IT?	STATUS	OBJECTIVE	TYPE	LINK
Orion	ODM-104	COMT inhibitor	Phase 2	Symptom relief	NCE	http://www.orion.fi/en/rd/orion-rd/pipeline/
Oryzon Genomics	ORY-2001	LSD-1 MAOB inhibitor	Phase 2a	Symptom relief	NCE	https://www.oryzon.com/en/therapeutic-programs/our-pipeline
The Parkinson Study Group/MJFF	Inosine	Urate precursor	Phase 3	Disease modifier	Repurpose	https://www.clinicaltrials.gov/ct2/show/NCT02642393?term=inosine&cond=Parkinson+Disease&rank=1
Peptron	PT 320 and 330	SR Exenatide 2 weeks	Phase 1	Disease modifier	Repurpose	http://www.peptron.com/ds2_2_1.html
Pharma Two B	P2B001	Rasagiline/pramipexole combination	Phase 3	Symptom relief	Reformulation	http://www.pharma2b.com/our-products/clinical-trials/
Pharnext	PXT864	Baclofen and acamprosate combination	Phase 1	Symptom relief	Repurpose	http://www.pharnext.com/en/pipeline-2/pxt-864
Prana Biotechnology/Takeda	PBT 434	Metal Protein Attenuating Compounds	Phase 1	Disease modifier	NCE	http://pranabio.com/news/prana-to-commence-phase-1-clinical-trial-of-pbt434-for-treatment-of-parkinsonian-diseases#.Wz57Ny3Mz_Q
Prothena/Roche	PRX002/RO7046015	Immunotherapy (Mab to aSN)	Phase 2	Disease modifier	NCE	https://www.prothena.com/pipeline/
QR Pharma	Posiphen	aSN (+tau +APP) aggregation inhibitor	Phase 2	Disease modifier	NCE	http://qrpharma.com/clinical/
Raqualia Pharma	RQ-0000010	Serotonin 4 receptor partial agonist	Phase 1	Symptom relief (constipation)	NCE	https://clinicaltrials.gov/ct2/show/NCT02838797
Saarland University	RESISTA-PD	Resistant starch	Phase 2	Symptom relief (constipation)	Repurpose	https://clinicaltrials.gov/ct2/show/NCT02784145
Sage Therapeutics	SAGE-217	GABA and NMDA receptor modulators	Phase 2	Symptom relief	NCE	https://www.sagerx.com/our-programs/ https://clinicaltrials.gov/ct2/show/NCT03000569
Sangamo Therapeutics	CERE-120	AAV-NTN gene therapy	Phase 2	Disease modifier	Gene therapy	https://clinicaltrials.gov/ct2/show/NCT00985517
Sanofi	Lixisenatide	GLP-1 agonist	Proof of concept	Disease modifier	Repurpose	https://clinicaltrials.gov/ct2/show/NCT03439943?term=lixisenatide&cond=parkinson%27s&rank=1
Sanofi/Genzyme		Inhibitor of aSN aggregation in patients with GCAsE mutations	Phase 2	Disease modifier	NCE	http://news.genzyme.com/press-release/sanofi-initiates-phase-2-clinical-trial-evaluate-therapy-genetic-form-parkinsons-disease https://clinicaltrials.gov/ct2/show/NCT02906020?term=moves-pd&rank=2
	GZ/SAR402671					
Serina Therapeutics	SER-214	Continuous delivery of rotigotine	Phase 1	Symptom relief	Reformulation	http://serinatherapeutics.com/pipeline/#ser-214
SK Biopharmaceuticals	YKP-10461	Selective, reversible MAO-B inhibitor	Phase 1	Disease modifier	NCE	http://www.skbp.com/index.asp
Sunovion (part of Sumitomo Dainippon)	DSP 6745	Serotonin 2A and 2C receptor antagonists	Phase 1	Symptom relief (PD psychosis)	NCE	http://www.sunovion.com/research-and-development/pipeline.html
Sunovion (part of Sumitomo Dainippon)	APL-130277	Apomorphine thin film strip	Submitted	Symptom relief	Reformulation	http://www.sunovion.com/research-and-development/pipeline.html
Sunovion (part of Sumitomo Dainippon)	SEP-363856	5-HT1 receptor agonist	Phase 2	Symptom relief (PD psychosis)	NCE	http://www.sunovion.com/research-and-development/pipeline.html
SynAgile	OraFuse	Continuous delivery of L-DOPA/Carbidopa	Phase 2a	Symptom relief	Reformulation	http://www.synagile.com/Company/SynAgile-News-2017-0824.php
TauRx	LMTX	Tau aggregation inhibitor	Phase 1	Disease modifier	NCE	http://taurx.com/pipeline.html
Teikoku Pharma	TPU-002	7-day rasagiline patch	Phase 1	Symptom relief	Reformulation	http://teikokuusa.com/research-and-development/pipeline/
Theranexus	THN102	Modafinil/flecainide combo	Phase 2	Symptom relief (daytime sleepiness)	Reformulation	https://www.theranexus.com/images/pdf/Theranexus_PR_Opening_Hungary_EN_vFinale.pdf
Titan Pharmaceuticals	Ropinirele implant	3 month depot	Phase 1/2	Symptom relief	Reformulation	https://www.titanpharm.com/news/press-releases/detail/181/first-patient-treated-with-titan-pharmaceuticals-subdermal
Transeuro		Fetal stem cells	Proof of concept	Disease modifier	Cells	http://www.transeuro.org.uk/index.html
US Worldmeds	INFUS-ON	Apomorphine infusion	Phase 3	Symptom relief	Reformulation	http://usworldmeds.com/research-development/#trials
Voyager Therapeutics	VY-AADC01	AV-hAADC gene therapy	Phase 2	Disease modifier	Gene therapy	http://www.voyagertherapeutics.com/our-approach-programs/pipeline/

PARKINSON'S THERAPIES IN DEVELOPMENT - RESEARCH PHASE

2 July 2018

Kevin McFarthing

COMPANY	THERAPY	WHAT IS IT?	STATUS	OBJECTIVE	TYPE	LINK
1st Biotherapeutics	1ST-101		Discovery	Disease modifier	NCE	http://www.1stbio.com/#focus
1st Biotherapeutics/Neuraly	1ST-102	c-Abl inhibitor	Pre-clinical	Disease modifier	NCE	https://www.prnewswire.com/news-releases/1st-bio-and-neuraly-collaborate-to-advance-novel-c-abl-inhibitors-for-parkinsons-disease-300542824.html
1st Biotherapeutics	1ST-103	Neuroinflammation inhibitor	Discovery	Disease modifier	NCE	http://www.1stbio.com/#focus
AC Immune	Morphomer aSN	Small molecule to inhibit aSN aggregation	Pre-clinical	Disease modifier	NCE	https://www.acimmune.com/en/pipeline-overview/
AC Immune		Antibodies to aSN and TDP-43	Discovery	Disease modifier	NCE	https://www.acimmune.com/en/pipeline-overview/
Acelot	JPS platform	LRRK2 inhibitors	Discovery	Disease modifier	NCE	http://acelot.com/lrrk2.html
Addex Therapeutics		mGluR4 PAM	Discovery	Disease modifier	NCE	https://www.addextherapeutics.com/en/pipeline/preclinical-pipeline/
Addex Therapeutics		Tyrosine receptor kinase PAMs	Discovery	Disease modifier	NCE	https://www.addextherapeutics.com/en/pipeline/preclinical-pipeline/
Affris	PD04	aSN vaccine	Pre-clinical	Disease modifier	NCE	http://www.affris.com/biotechnology/our-impact/pipeline/
Air Liquide Sante	Inhaled xenon		Pre-clinical	Symptom relief (LID)	Reformulation	https://onlinelibrary.wiley.com/doi/full/10.1002/mds.27404
Alkahest	GRF6019	Plasma protein extract	Pre-clinical	Disease modifier	Protein extract	http://www.alkahest.com/2018/02/12/alkahest-receives-grant-from-michael-j-fox-foundation-funding-will-support-the-clinical-development-of-a-novel-parkinsons-therapy/
Alnylam		siRNA	Pre-clinical	Disease modifier	NCE	http://investors.alnylam.com/news-releases/news-release-details/alnylam-reports-preclinical-data-demonstrating-central-nervous
Amabiotics	AMA-101	Microbiome modifier? Not clear.	Pre-clinical	Disease modifier	NCE	http://www.amabiotics.com/applications/
American Gene Technologies	AG-PD	Therapeutic lentivirus	Discovery	Disease modifier	NCE	https://americangene.com/development-portfolio/parkinsons/
Amarantus Bioscience	MANF	Mesencephalic astrocyte-derived neurotrophic factor	Pre-clinical	Disease modifier	NCE	http://www.amarantus.com/therapeutics-pipeline/overview
Anavex Life Sciences	3-71	Targets sigma receptors	Pre-clinical	Disease modifier	NCE	http://www.anavex.com/#1/aboutus
Anavex Life Sciences	1-41	Targets sigma receptors	Pre-clinical	Disease modifier	NCE	http://www.anavex.com/#1/aboutus
Antoxis	Proxison	Inhibits oxidative stress	Discovery	Disease modifier	NCE	http://www.antoxis.com/technology/technology
APeT Holding BV	Constadopa	Twice daily dosing	Discovery	Symptom relief	NCE	http://www.apetholding.com/medication.htm
Appello		mGluR4 PAM	Pre-clinical	Symptom relief	NCE	https://www.fiercebitech.com/biotech/newcomer-appello-raises-10-5m-for-new-vanderbilt-parkinson-s-drug
Aposense	ATT-LD	L-DOPA prodrug	Pre-clinical	Symptom relief	NCE	http://www.aposense.com/sites/default/files/Aposense%20ATT11T.pdf
Armagen	AGT-115	Modified EPO	Pre-clinical	Disease modifier	NCE	http://armagen.com/compounds/agt-115-for-parkinsons-disease-and-stroke/
Armagen	AGT-190	Modified GDNF	Pre-clinical	Disease modifier	NCE	http://armagen.com/compounds/agt-190-for-parkinsons-disease-and-stroke/
Arrien Pharmaceuticals	ARN-1104	LRRK2 inhibitor	Pre-clinical	Disease modifier	NCE	http://www.arrienpharma.com/arrienpipeline_overview.html
Asceneuron		M1 PAM	Discovery	Symptom relief (PDD)	NCE	https://www.asceneuron.com/pipeline
Astraea Therapeutics	AT-390 and AT-403	NOP receptor agonists	Pre-clinical	Symptom relief (LID)	NCE	http://www.astraeatherapeutics.com https://scienceofparkinsons.com/2018/04/04/is-there-nop-hope-for-parkinsons/
Axial Biotherapeutics		Microbiome and PD	Research program	Disease modifier	NCE	https://www.axialbiotherapeutics.com/2018/06/parkinsons-institute-and-clinical-center-and-axial-biotherapeutics-announce-collaboration-to-target-gastrointestinal-metabolites-that-may-contribute-to-parkinsons-disease/
BenevolentAI bio/PUK/CPT			Research program	Disease modifier	NCE	https://benevolent.ai/news/announcements/medical-ai-award-sets-its-sights-on-treating-parkinsons/
Berg Health		Interrogative biology	Discovery	Disease modifier	NCE	http://berghealth.com/therapeutics/
Bioarctic (partnered with Eisai and Abbvie)	BAN0805	aSN antibody	Pre-clinical	Disease modifier	NCE	https://www.bioarctic.se/en/pipeline-1921/
Blackthorn Therapeutics	BTRX-246040	NOP receptor antagonists	Pre-clinical	Symptom relief (LID)	NCE	http://www.blackthornrx.com/blackthorn-therapeutics-presents-preclinical-and-clinical-data-from-its-first-in-class-nopr-antagonist-at-american-college-of-neuropsychopharmacology-annual-meeting/
Blue Rock therapeutics (+ Bayer)	IPSC research	iPSC	Research program	Disease modifier	Stem cells	http://bluerocktx.com/pipeline/
Brainstorm Cell Therapeutics		MSC-NTF cells	Pre-clinical	Disease modifier	Stem cells	http://www.brainstorm-cell.com/pipeline/preclinical/
Carmot Therapeutics/Amgen		Discovery programme	Discovery	Disease modifier	NCE	http://carmot-therapeutics.us/2017/12/06/carmot-enters-a-multi-year-drug-discovery-collaboration-with-amgen-collaboration-aims-to-identify-novel-molecules-intended-for-parkinsons-disease/
Cantabio Pharmaceuticals	CB101	Targets DJ-1	Pre-clinical	Disease modifier	NCE	http://www.cantabio.com/scientific-approach/pipeline
Cantabio Pharmaceuticals	CB201	Cell penetrant DJ-1 protein	Pre-clinical	Disease modifier	NCE	http://www.cantabio.com/scientific-approach/pipeline
Carna Biosciences		Targets kinases	Discovery	Disease modifier	NCE	http://www.fisco.co.jp/uploads/carnabio20180413_e.pdf
Casma Therapeutics		Autophagy enhancers	Pre-clinical	Disease modifier	NCE	https://www.casmatx.com/therapeutic-focus/ https://www.fiercebitech.com/biotech/casma-launches-58-5m-for-treatments-targeting-cell-s-garbage-disposal
Cellix Bio	CLX-107	L-DOPA/Carbidopa	Pre-clinical	Symptom relief	NCE	https://www.cellixbio.com/pipeline.html http://slideplayer.com/slide/12734254/
Cerevance			Pre-clinical	Disease modifier	NCE	https://www.cerevance.com/pipeline
Charles River/MJFF		LRRK2 small molecule inhibitors	Research program	Disease modifier	NCE	https://www.fiercebitech.com/cro/charles-river-fox-foundation-renew-parkinson-s-collab?utm_medium=nl&utm_source=internal&mkid=816428&mkt_tok=eyJpIjoiTlJlKBFiGzJmNmV4TVdVMClslhQlOjYTYFYClvka1RqRGkNzI2aHNhdFwvakhLVDA5UTZKOZQYmRuUjNlPy2pYlFwNjNlPVGhCQ0lEZ05yazNyZFBvcW5vW2pDNilrWGZvcUhhQm dRMnVNUVNGWmdWUXFwZEpLzFKXC8zdjMz3BsQkZS2ZDVSN2NkRWRkVW95SjNlY3BoMyJ9

COMPANY	THERAPY	WHAT IS IT?	STATUS	OBJECTIVE	TYPE	LINK
Chipscreen	Chigitazar	PPAR Pan inhibitor	Pre-clinical	Disease modifier	NCE	http://www.chipscreen.com/En/ProductLine/index.html
Cleavel/Kaldi/Domain	CVXL-0069	Dual adenosine receptor inhibitor	Pre-clinical	Symptom relief (MS and NMS)	NCE	http://www.cleavelpharma.com/en/cvxl-0069/
Cure Parkinson's Trust/University of Queensland	MCC 950	Inflammasome inhibitor	Pre-clinical	Disease modifier	Repurpose	https://www.cureparkinsons.org.uk/news/reducing-inflammation-using-cancer-drug
Curemark	CM-PK	?	Pre-clinical	Symptom relief (LID)	NCE	http://curemark.com/our-work/pipeline/parkinsons-disease/
Denali Therapeutics	ATV:aSyn	Antibody	Pre-clinical	Disease modifier	NCE	https://www.denalitherapeutics.com/develop/#pipeline
Dermaxon	DX0308	Retinoic acid metabolism inhibitor	Pre-clinical	Disease modifier	NCE	http://dermaxon.com/pipeline/
Domain therapeutics/Mavalon therapeutics	DT011088	mGluR3 allosteric modulator	Discovery	Symptom relief	NCE	http://www.domaintherapeutics.com/pipeline/pipeline.html
Domain therapeutics e-Therapeutics/C4X		mGluR4 allosteric modulator	Discovery Research program	Symptom relief Disease modifier	NCE NCE	http://www.domaintherapeutics.com/pipeline/pipeline.html https://parkinsonsnewstoday.com/2018/05/09/e-therapeutics-c4x-discovery-collaborate-find-parkinsons-strategies/?amp
Eli Lilly	DETQ	D1 potentiator	Pre-clinical	Symptom relief	NCE	http://europepmc.org/abstract/med/29102759
Eli Lilly/Medtronic	GDNF variant	Growth factor	Pre-clinical	Disease modifier	NCE	https://www.sciencedirect.com/science/article/pii/S0028390818302338
Emerald Health Pharmaceuticals	EHP-102	Antiinflammatory cannabinoid	Pre-clinical	Disease modifier	NCE	http://emeraldpharma.life/pipeline/
Forma therapeutics/U of Oxford		Research program	Research program	Disease modifier	NCE	https://www.businesswire.com/news/home/20180509005811/en/FORMA-Therapeutics-University-Oxford-Announce-Multi-Year-Collaboration
Fortuna Fix/New World Laboratories		Personalised neural stem-like cells	Discovery	Disease modifier	NCE	https://www.fiercebitech.com/biotech/amgen-makes-regenerative-medicine-play-backing-25m-fortuna-round-to-move-neural-stem-cells https://nwl.net/en/neural-stem-like-cells/
Fulcrum Therapeutics		Influence genetic control	Discovery	Disease modifier	NCE	http://www.fulcrumtx.com/pipeline/
Genecode		GDNF family ligand (GFL) mimetics	Discovery	Disease modifier	NCE	http://www.genecode.com/research-and-development-directions/parkinsons-disease-2/
Genentech		Discovery	Discovery	Disease modifier	NCE	https://www.gene.com/scientists/neuroscience
Genkyotex		NADPH oxidase inhibitors	Discovery	Disease modifier	NCE	https://www.genkyotex.com/en/pipeline/earlier-stage-programs
ICB International		SMART molecules targeting aSN	Discovery	Disease modifier	NCE	http://icbi.com/parkinsons-disease/
Immugenetics		ABC transporter protein enhancers	Pre-clinical	Disease modifier	NCE	http://www.immugenetics.com/pipeline
Inhibikase Therapeutics	IKT-148009	Abi kinase inhibitor	Pre-clinical	Disease modifier	NCE	https://www.inhibikase.com/pipeline/ikt-148009-for-parkinsons-disease/
Integrative research laboratories	IRL448/IRL555	?	Discovery	Symptom relief (LID)	NCE	http://www.irlab.se/programmes/
Jeil Pharmaceutical		Stem cell discovery programme	Discovery	Disease modifier	Cells	https://www.jeilpharm.co.kr/eng/03_r&d/sub_03_01.html
Junaxo	JNX3001	Trehalose as autophagy enhanceer	Pre-clinical	Disease modifier	Repurpose	http://www.junaxo.com/jnx3001.html
Keapstone Therapeutics		Discovery programme	Discovery	Disease modifier	NCE	https://www.parkinsonsvirtualbiotech.co.uk
Khondrion	KH176	Prevents mitochondrial dysfunction	Pre-clinical	Disease modifier	NCE	http://www.khondrion.com
Lead Discovery Center		LRRK2 programme	Discovery	Disease modifier	NCE	http://www.lead-discovery.de/en/strategy/
Longevity Biotech	LBT-3627	VIP receptor agonist	Pre-clinical	Disease modifier	NCE	http://longevitybiotech.com/?p=1109
Lundbeck	PFE-360	LRRK2 inhibitor	Pre-clinical	Disease modifier	NCE	http://www.lundbeck.com/global/brain-disorders/research-and-development
Lyosomal Therapeutics/Allergan	LTI-291	Gcase inhibitor	Pre-clinical	Disease modifier	NCE	https://www.lyosomaltx.com
Mavalon Therapeutics/Domain		mGluR3 PAM	Discovery	Disease modifier	NCE	http://www.domaintherapeutics.com/pipeline/pipeline.html
Melior Pharmaceuticals	MLR-1017	Psychostimulant	Pre-clinical	Symptom relief	Repurpose	http://www.meliiorpharmaceuticals.com/pipeline_mlr1017.html https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=848
Merck/Parkinson's Institute		LRRK2 inhibitors	Pre-clinical	Disease modifier	NCE	https://www.businesswire.com/news/home/20180205005032/en/Parkinson's-Institute-Clinical-Center-Collaborates-Merck-Evaluate
Metabolic Solutions Development	MSDC-0160	mTOT modulator	Pre-clinical	Disease modifier	NCE	http://www.msdrx.com/pipeline/msdc-0160
Michael J Fox Foundation/Binghamton U/Wayne State U	D-512	D2/D3 receptor agonist	Pre-clinical	Disease modifier	NCE	https://www.europeanpharmaceuticalreview.com/news/64732/new-drug-may-parkinsons-disease/
Minerva Neurosciences	MIN-301	Neuregulin 1b1 peptide	Pre-clinical	Disease modifier	NCE	http://www.minervaneurosciences.com/innovation-pipeline/min-301/
Mission Therapeutics		USP30 targets	Pre-clinical	Disease modifier	NCE	http://missiontherapeutics.com/pipeline/usp30-neurodegenerationparkinsons-disease-program/
Mitochon Pharmaceuticals	MP-201	Mitochondrial modulator	Discovery	Disease modifier	NCE	https://www.mitochonpharma.com/pipeline/
Modag/Cure Parkinson's Trust	Anle 138b	Inhibits aSN oligomerisation	Pre-clinical	Disease modifier	NCE	http://www.modag.net
Montisera	D15.3	?	Discovery	Disease modifier	Botanical	https://www.montisera.com/pipeline/
Motac		D3 receptor agonists / u opioid receptor antagonists 5-HT1a agonists	Discovery	Symptom relief	NCE	http://motac.com/ip/
Netherlands Translational Research Centre		Tryptophan oxygenase target	Discovery	Disease modifier	NCE	https://www.ntrc.nl/projects/parkinsons-disease/
Neuraltus	NP001 (IV sodium chlorite)	Regulates activated macrophages	Pre-clinical	Disease modifier	NCE	http://www.neuraltus.com/cns/
Neurodyn	ND1208	Neuroprotectant	Discovery	Disease modifier	NCE	http://neurodyn-inc.com/pipeline/
Neurodyn	Progranulin ND 602	Neuroprotectant	Discovery	Disease modifier	NCE	http://neurodyn-inc.com/pipeline/
Neurolix	NLX-112	5HT-1A inhibitor	Pre-clinical	Symptom relief (LID)	NCE	http://www.neurolix.com/en/company/pipeline/nlx-112.html
Neuronascent	NNI-362 and NNI370 (backup)	Neurorestorative	Discovery	Disease modifier	NCE	http://www.neuronascent.com/r&d-parkinsons.htm
nLife Therapeutics	NLF-PD 1233	Antisense oligo/drug conjugates	Discovery	Disease modifier	NCE	https://n-life.es/cns-programs/
NLS Pharma		Quinolone	Pre-clinical	Symptom relief	Repurpose	http://nlspharma.com/science/pipeline/
NLS Pharma		Tryptamine	Pre-clinical	Symptom relief	Repurpose	http://nlspharma.com/science/pipeline/
NLS Pharma		Aminoquinoline	Pre-clinical	Symptom relief	Repurpose	http://nlspharma.com/science/pipeline/
Novo Nordisk/U of Lund/Biolamina		Stem cell research program	Research program	Disease modifier	Stem cells	https://www.lunduniversity.lu.se/article/collaboration-between-lund-university-researchers-and-novo-nordisk-paves-the-way-for-large-scale-cell-therapy-against-parkinsons-disease
Nutriband (acquired 4P Therapeutics)	Transdermal apomorphine		Pre-clinical	Symptom relief	Reformulation	http://4ptherapeutics.com/pipeline/
OPKO Health	SR-3306	jun-terminal kinase inhibitors	Discovery	Disease modifier	NCE	http://www.opko.com/therapeutics/parkinsons/
OxStem		Endogenous cell activation therapy	Research program	Disease modifier	NCE	http://www.oxstem.co.uk/product-pipeline/neuro
Parkure			Pre-clinical	Disease modifier	Repurpose	http://parkure.co.uk/parkures-pipeline-news-two-drugs-pre-clinically-validated/
Peptron	PT 304	SR Exenatide 1 month	Pre-clinical	Disease modifier	Repurpose	http://www.peptron.com/ds3_1_1.html
Pharmatrophix	P75 small molecule receptor program	Prevents neurodegeneration	Discovery	Disease modifier	NCE	http://pharmatrophix.com/ptx-technology.html

COMPANY	THERAPY	WHAT IS IT?	STATUS	OBJECTIVE	TYPE	LINK
Plex Pharmaceuticals/Collidion		Targets misfolded proteins	Discovery	Disease modifier	NCE	https://www.plexpharma.com/drug-programs
Priavoid		All-D-peptides	Discovery	Disease modifier	NCE	https://priavoid.com/pipeline/
Prevail Therapeutics		NAV AAV9 vector	Research program	Disease modifier	Gene therapy	http://www.businesswire.com/news/home/20170809005304/en/
Primary Peptides	PP-003	Small peptide decreasing aSN	Pre-clinical	Disease modifier	NCE	http://www.primarypeptides.com/research/parkinsons-disease/
Proclara (formerly Neurophage)	GAIM	Targets misfolded proteins	Pre-clinical	Disease modifier	NCE	http://www.proclarabio.com/our-programs/
PromIS Neurosciences		aSN antibody	Discovery	Disease modifier	NCE	https://promisneurosciences.com/product-portfolio/
Promius Pharma/Dr Reddy's		Research program	Pre-clinical	?	?	http://promiuspharma.com/innovation/pipeline/
Proteostasis Therapeutics (+Biogen)		USP14 inhibitors	Discovery	Disease modifier	NCE	http://www.proteostasis.com/product-pipeline/novel-strategies/
ReMYND/Novo Nordisk	ReS9-S and ReS12-S	Modifying aSN toxicity	Pre-clinical	Disease modifier	NCE	https://www.remynd.com/platform-products#anchor-node-232
Retrotope		Prevent cell damage from oxidative stress	Discovery	Disease modifier	NCE	http://www.retrotope.com
Rodin Therapeutics		Epigenetic regulation	Research program	Disease modifier	NCE	https://rodintherapeutics.com/about/
Sage Therapeutics	SAGE-234	GABA and NMDA receptor modulators	Pre-clinical	Symptom relief	NCE	https://www.sagerx.com/our-programs/
SanBio	SB623	Cell therapy	Pre-clinical	Disease modifier	Cells	http://www.san-bio.com/corporate/business.html
Saniona		Nicotinic a6 receptor modulators	Pre-clinical	Disease modifier	NCE	https://saniona.com/pipeline
Sheffield University	Ursodeoxycholic acid	Improve mitochondrial dysfunction	Pre-clinical	Disease modifier	Repurpose	https://www.cureparkinsons.org.uk/trials-pending
Synpromics/UCL		Synthetic gene promoters	Research program	Disease modifier	NCE	http://www.businesswire.com/news/home/20171127005490/en/Synpromics-Announces-Collaboration-UCL-Develop-Revolutionary-Gene
Synthonics	Metal coordinated pharmaceuticals	Extend absorption phase of L-DOPA	Discovery	Symptom relief	Reformulation	http://www.synthonicsinc.com/science.aspx
TauRx		G2 PD	Pre-clinical	Disease modifier	NCE	http://taurx.com/uploads/pres%20releases/Alzheimer%20candidate%20LMTX%20inhibits%20a-syn%20aggregation%20in%20pre-clinical%20Parkinson's%20Disease%20study,%20published%20in%20the%20Frontiers%20in%20Molecular%20Neuroscience.pdf
Technophage		TZ-113	Pre-clinical	Disease modifier	NCE	http://www.technophage.pt/index.php/fr-d/product-pipeline
UCLA	CLR01	Binds to lysine residues to prevent aSN aggregation	Pre-clinical	Disease modifier	NCE	http://newsroom.ucla.edu/releases/movement-restored-in-animal-model-of-parkinsons-disease?_ga=2.196790053.828988578.1498489151-1959190442.1498489151?_ga=2.196790053.828988578.1498489151-1959190442.1498489151
Verge Genomics/ECSD/VIB		Single cell sequencing	Research program	Disease modifier	Target discovery	https://www.prnewswire.com/news-releases/verge-genomics-announces-landmark-effort-to-generate-first-single-cell-data-from-patients-with-parkinsons-disease-300651394.html?tc=eml_cleartime
VistaGen Therapeutics	AV-101 (L-4-chlorokynurene or 4-Cl-KYN)	NMDAR GlyB modulator	Discovery	Disease modifier	NCE	http://www.vistagen.com/pipeline/potential-future-indications
VivaCell Biotechnology	VCE-003.2	Cannabinoid derivatives	Discovery	Disease modifier	NCE	http://vivacellspain.com/en/page.cfm?id=49&title=pipeline
Vivreon Biosciences	VV-4000	Microglial calcium-release activated channel inhibitors	Discovery	Disease modifier	NCE	http://www.vivreonbiosciences.com/pipeline.html
Wellstat Therapeutics	WT501	Oral agent for mitochondrial disease	Discovery	Disease modifier	NCE	http://www.wellstattherapeutics.com/therapeutics/html/randd/compounds/WT501.html
Xoc Pharmaceutical	XC130	Dopamine agonist	Pre-clinical	Symptom relief	NCE	http://www.xocpharma.com
Yumanity Therapeutics/Nikon		Protein misfolding	Research program	Disease modifier	NCE	https://www.nikon.com/news/2018/0328_01.htm

PARKINSON'S THERAPIES - INACTIVE

2 July 2018

These therapies are either on the market; actively stopped; or I am unable to find credible up to date information.

Kevin McFarthing

COMPANY	THERAPY	WHAT IS IT?	STATUS	OBJECTIVE	TYPE	LINK
Acorda Therapeutics (Biotie)	Tozadenant SYN-115	A2a inhibitor	Phase 3	Symptom relief	NCE	http://www.biotie.com/product-portfolio/syn115.aspx?sc_lang=en
Celceutix	KM362	Stops demyelination	Discovery	Disease modifier	NCE	http://celceutix.com/pre-clinical-compounds/#sthash.e050454Z.dpbs
Euroscreen/Ogeda	ESN502	?	Discovery	?	NCE	https://www.ogeda.com/pipeline-products/other-programs
FPRT Bio	XPro1595	TNF modifier to prevent neuroinflammation	Pre-clinical (inactive?)	Disease modifier	NCE	http://fprtbio.dreamhosters.com/products/
Intermed Discovery	IMD-026259	HIF-1 inhibitor	Discovery	Disease modifier	NCE	https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=610
Xenoport/Arbor Pharma	XP21279	L-DOPA pro drug	Suspended	Symptom relief	NCE	http://www.xenoport.com/pipeline/
Adamas Pharma	ADS-5102	Extended-release amantadine	Approved	Symptom relief (LID)	Reformulation	https://www.bioportfolio.com/news/article/3343410/Adamas-Pharmaceuticals-initiates-a-Phase-2-3-Clinical-Study-of-ADS-5102.html
Impax Pharma	IPX-066/Rytary	L-DOPA/carbidopa extended release	Approved	Symptom relief	Reformulation	http://www.impaxpharma.com/rd_focus/product_pipeline
Osmotica Pharmaceutical	Osmolex-ER	Extended release amantadine	FDA approved	Symptom relief (LID)	Reformulation	http://www.osmotica.com/PDF/Osmotica_Release_2_19_18_FINAL.pdf
Astra Zeneca	AZD3241	Myeloperoxidase inhibitor	Discontinued	Disease modifier	NCE	https://clinicaltrials.gov/ct2/show/NCT01603069
Michael J Fox Foundation	Glutathione	Antioxidant	Phase 2	Disease modifier	Repurpose	https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1378
Neuronova (now Newron)	PDGF-BB	Growth factor	Phase 1/2	Disease modifier	NCE	https://clinicaltrials.gov/ct2/results?cond=&term=sNN0031&cntry=&state=&city=&dist=
Prana Biotechnology	Clioquinol	Lysosome enhancer	Proof of concept	Disease modifier	Repurpose	https://patents.google.com/patent/US5980914
Pfizer	SD-1077	Dopamine signalling modulator	Phase 2	Symptom relief	NCE	https://clinicaltrials.gov/ct2/show/NCT02847650
Sellas	PF-06649751 Zolpidem	Selective GABA-A-BZ1 receptors	Phase 2	Symptom relief	Repurpose	http://sellaslifeosciences.com/biopharma/pipeline-and-rd/zolpidem/
Teva	SD-1077	Deulevodopa	Phase 1	Symptom relief	Reformulation	http://www.tevapharm.com/research_development/rd
Uniquire/UCSF/NIH	AMT-140	Gene therapy with AAV2-GDNF	Phase 1	Disease modifier	Gene therapy	http://www.uniquire.com/about/partners.php
Heptares	NSI-566	mGluR5 inhibitors	Discovery	Disease modifier	NCE	http://www.heptares.com/pipeline/
Neuralstem	NSI-566	Cell therapy	Pre-clinical	Disease modifier	Cells	http://www.neuralstem.com/patient-info-treatments-in-development#pd
NSGene/Takeda	NsG0301	Cell repair platform delivering GDNF	Pre-clinical	Disease modifier	NCE	http://nsgene.dk/NsGene-410.aspx https://www.takeda.com/newsroom/newsreleases/2016/takeda-and-nsgene-partner-to-perform-research-in-cell-encapsulation-therapies-for-parkinsons-disease/
Park Cell		Autologous cell transplantation	Pre-clinical	Disease modifier	Cells	http://parkcell.se/research-development/
Pfizer		Research program	Discovery	Disease modifier	NCE	http://www.pfizerneuroscience.com/about-us
Promentis		Glutamergic discovery program	Discovery	Disease modifier	NCE	http://www.promentispharma.com/technology/
Reset Therapeutics		Orexin receptor modulators	Discovery	Symptom relief (sleep)	NCE	http://resettherapeutics.com/programs/
Rhinocyte		Nasal derived stem cells	Discovery	Disease modifier	Stem cells	http://www.rhinocyte.com
STATegics		Cytokine receptor modulators	Discovery	Disease modifier	NCE	http://www.stategics.com/first_2.html
University of New Mexico	Flubendazole	Promotes autophagy	Pre-clinical	Disease modifier	Repurpose	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624223/
Ono Pharmaceuticals	ONO-2160	L-DOPA prodrug +carbidopa	Phase 1	Symptom relief	NCE	https://www.ono.co.jp/eng/investor/pdf/ir/2017/0802/
Vernalis	V81444	Adenosine receptor antagonist	Phase 1	Symptom relief	NCE	https://clinicaltrials.gov/ct2/show/NCT02764892?term=V81444&rank=1
Aeolus Pharmaceuticals	AEOL 11114	Reduces oxidative stress	Pre-clinical	Disease modifier	NCE	http://www.aolsrx.com/product-pipeline/aeol-11114
Angita	AG-0029	D2 agonist/H3 antagonist	Discovery	Symptom relief	NCE	http://www.angitapharma.com/projects-and-research/q2-aaonism/
Aracion Biotech	S14	PDE-7 inhibitor	Pre-clinical	Disease modifier	NCE	http://www.aracion.com/alzheimer/science-and-research/research-areas/therapy/?lang=en
Ensemble therapeutics		Cyclophilin antagonists	Pre-clinical	Disease modifier	NCE	https://endpts.com/investors-cut-their-losses-quietly-shutter-ensemble-therapeutics-as-pipeline-plans-fizzle-out/
Fabre-Kramer Pharmaceuticals	FKK01PD	Apomorphine prodrugs	Pre-clinical	Symptom relief	NCE	http://www.fabrekramer.com/?page_id=78
Gene Solutions		mtDNA focused discovery program	Discovery	Disease modifier	NCE	http://www.mitodna.com/disease-focus.html
Genosco		LRRK2 inhibitors	Discovery	Disease modifier	NCE	http://www.genosco.com/company-overview
M's Science Corporation	MC116	Sigma 1 receptor agonist	Pre-clinical	Disease modifier	NCE	http://www.m-sci.com/e/index.html
M et P Pharma		Nasal delivery of dopamine	Pre-clinical	Symptom relief	Reformulation	http://www.mattern-pharma.com/pipeline_5.php
Mitodys Therapeutics			Discovery	Disease modifier	NCE	http://www.mitodys.com/the-diseases.html
Neurop	Glu N2C/D	NMDA receptor blocker	Discovery	Symptom relief	NCE	http://www.neuropinc.com/pipeline/
New World Laboratories	NWL-283	Cell regeneration peptides	Discovery	Disease modifier	NCE	https://nwl.net/en/cell-regeneration-peptides/
Vanton Research Labs	ODT-SR	Orally dissolving L-DOPA and carbidopa	Pre-clinical	Symptom relief	Reformulation	http://www.pharmacychoice.com/news/article.cfm?Article_ID=1510178 http://www.pharmosa.com.tw/en/pipeline.htm